RKRayan Kabirian

Rayan Kabirian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rayan Kabirian has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

    by Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, et al.

    Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC) systemic treatments. The exposure group consisted of reports mentioning a BC treatment at any time during pregnancy. The primary outcome was the reporting odds ratio (ROR) of maternal–fetal complications with the two cornerstone cytotoxic classes, anthracyclines (doxorubicin, epirubicin) and taxanes (docetaxel, paclitaxel), assessed individually vs. other anticancer treatments. Secondary analyses assessed all BC treatments and trimester‐specific risks. Of 3310 pregnancy‐related reports, 1789 involved BC treatments. Median maternal age was 27.4 years (SD 13.8) vs. 29.3 (SD 11.7) in the comparator group. Adverse maternal–fetal outcomes were reported in 998 (55.8%) BC treatment reports vs. 470 (30.9%) in other anticancer treatments. Anthracyclines were associated with neonatal hematologic disorders (ROR = 1.7, 95% CI = 1.1–2.5) and intrauterine growth restriction (IUGR) (ROR = 2.1, 95% CI = 1.7–2.7). Paclitaxel was linked to sensory defects including congenital ear/ocular anomalies (ROR = 5.2, 95% CI = 2.2–12.3); all 8 cases involved platinum co‐exposure (cisplatin: n = 5; carboplatin: n = 3), suggesting a platinum‐mediated mechanism; and to hyperbilirubinemia (ROR = 4.1, 95% CI = 2.0–8.4), and docetaxel to neonatal neurologic disorders (ROR = 3.6, 95% CI = 1.4–9.3). First‐trimester exposure ( n = 26) showed preliminary signals of increased congenital malformation risk, including face (ROR = 13, 95% CI = 2–79), and musculoskeletal malformation (ROR = 8, 95% CI = 1.1–60). This pharmacovigilance study identifies signals of disproportionate reporting of specific maternal and neonatal outcomes with BC treatments; these findings are hypothesis‐generating and require confirmation in prospective registries.


  • Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study)

    by Rayan Kabirian, Mathilde de Saint Ghislain, Olivia Le Saux, Laurent Mathiot, Jean-Sébastien Frenel, Paule Augereau, Alexandra Forestier, Jean David Fumet, Lauriane Eberst, Stanislas Quesada, et al.


  • Open Access

    Pregnancy Desire and Pregnancy Attempt: Why Words Matter in Reproductive Research — A Nationwide cross-sectional Cohort Study

    by Rayan Kabirian, Raphaëlle Bas, Agathe Chabassier, Clara Sebbag, Christine Rousset-Jablonski, Angelique Bobrie, Florence Coussy, Marie Préau, Marc Espie, Elise Dumas, et al.

    Objective: To quantify the gap between pregnancy desire and pregnancy attempts among young women with and without a history of breast cancer (BC), and to identify factors associated with this gap. Design: Cross-sectional cohort study. Setting: The FEERIC study, conducted in France. Population: Women aged 18–43 years without or with prior BC filling inclusion forms of a collaborative study. Methods: Pregnancy desire was assessed by self-report (“Do you currently desire a pregnancy?”). Attempt was defined as engaging in unprotected intercourse with the intention to conceive. The pregnancy desire–attempt gap was defined as expressing a desire for pregnancy without actively trying to conceive. Logistic regression was used to evaluate associated demographic, clinical, and treatment-related factors. Main outcome measures: Prevalence of the pregnancy desire–attempt gap and predictors of this gap among BC survivors. Results: Of 4,351 participants (517 with BC and 3,834 controls), 735 (16.9%) reported a pregnancy desire with 54% attempting conception and 46% who did not. The desire–attempt gap was significantly more frequent in women with a history of BC (OR=1.62, 95%CI[1.15–2.30]). Among BC survivors, younger age (<30years), nulliparity, being single, and ongoing endocrine therapy were independently associated with the gap, whereas prior chemotherapy or trastuzumab were not. Conclusions: Nearly half of women declaring desiring pregnancy do not initiate pregnancy attempts, with a larger gap among BC survivors. These findings highlight the need to explore both medical barriers and psychosocial determinants underlying this gap and underscore the importance of refining the language used in reproductive research. Funding: This study was supported by “SHS INCa” grant no.2016-124 and is part of a research project on young women funded by Monoprix*.

  • Open Access

    From Pregnancy Desire to Pregnancy Attempt: Why Words Matter in Reproductive Research — A Nationwide Prospective Cohort Study

    by Rayan Kabirian, Raphaëlle Bas, Agathe Chabassier, Clara Sebbag, Christine Rousset-Jablonski, Angelique Bobrie, Florence Coussy, Marie Préau, Marc Espie, Elise Dumas, et al.

    [1]¿p#1 Objective To quantify the gap between pregnancy desire and pregnancy attempts among young women with and without a history of breast cancer (BC), and to identify factors associated with this gap. Design Nationwide prospective cohort study. Setting The FEERIC study, conducted in France. Population Women aged 18–43 years with or without prior BC who completed baseline and six-monthly follow-up questionnaires for up to three years. Methods Pregnancy desire was assessed by self-report (“Do you currently desire a pregnancy?”). Attempts were defined as engaging in unprotected intercourse with the intention to conceive. The pregnancy desire–attempt gap was defined as expressing a desire for pregnancy without actively trying to conceive. Logistic regression was used to evaluate associated demographic, clinical, and treatment-related factors. Main outcome measures Prevalence of the pregnancy desire–attempt gap and predictors of this gap among BC survivors. Results Of 4,351 participants(517 with BC and 3,834 controls), 735(16.9%) reported a pregnancy desire at inclusion. During follow-up, 54% attempted conception and 46% did not. The desire–attempt gap was significantly more frequent in women with BC (OR=1.62, 95%CI[1.15–2.30]). Among BC survivors, younger age (Conclusions Nearly half of women desiring pregnancy did not initiate attempts, with a larger gap among BC survivors. These findings highlight the need for integrated fertility counseling and psychosocial support in survivorship care.

  • Open Access

    BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase

    by Aurélie Cabannes‐Hamy, Rayan Kabirian, Floriane Jochum, Kevin Bihan, Elise Dumas, Florence Coussy, Enora Laas, Philippe Rousselot, Sylvain Choquet, Madalina Uzunov, et al.

    Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have greatly improved the survival of patients with chronic myeloid leukemia (CML), and their teratogenicity appears as an important factor for individuals of childbearing potential. This study aims to investigate pregnancy and fetal/newborn adverse outcomes resulting from exposure to BCR::ABL1‐TKIs during pregnancy. For this disproportionality analysis, we used the WHO's global VigiBase up to January 2024, and included reports involving pregnancy, antineoplastic treatment during pregnancy, and cancer. The exposure group consisted of reports mentioning BCR::ABL1‐TKIs at any time during pregnancy. The primary outcome was the reporting odds ratio (ROR) of maternal‐fetal complications in the BCR::ABL1‐TKIs group compared to other anticancer treatments. The analysis included 3,389 reports (TKI = 969; other = 2,420). In the BCR::ABL1‐TKI‐exposed group, the mean age was 28.9 years, and 724 patients (92.2%) were treated for CML. BCR::ABL1‐TKIs were mainly imatinib (n = 642, 66.3%), nilotinib (n = 218, 22.5%), and dasatinib (n = 127, 13.1%) reported without other non‐TKI anticancer agents(92.3%). Compared to other anticancer drugs, overreported outcomes with TKIs included hydrops fetalis (ROR = 13 [95%CI = 1.5–110], P = 0.009), polyhydramnios (ROR = 5 [1.3–20], P = 0.02), and threatened preterm labor (ROR = 10 [1.1–90], P = 0.03). When analyzing specific molecule effects, hydrops fetalis (ROR = 27 [5.4–130], P = 0.001) and polyhydramnios (ROR = 13 [3.3–54], P = 0.004) were overreported with dasatinib. In this large cohort of 969 individuals exposed to TKIs during pregnancy, dasatinib use was associated with most BCR::ABL1‐TKI‐specific toxicities and should be avoided during pregnancy. Fewer or no adverse events were overreported with imatinib and nilotinib.


  • Open Access

    TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer

    by Rayan Kabirian, Olivier Tredan, Frederik Marmé, Xavier Paoletti, Lauriane Eberst, Coriolan Lebreton, Thibault De La Motte Rouge, Renaud Sabatier, Antoine Angelergues, Michel Fabbro, et al.

    Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.Clinical Trial Registration: NCT04713514 (ClinicalTrials.gov).


  • Open Access

    The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS)

    by Elise Dumas, Lucie Laot, Florence Coussy, Beatriz Grandal Rejo, Eric Daoud, Enora Laas, Amyn Kassara, Alena Majdling, Rayan Kabirian, Floriane Jochum, et al.

    Background: Breast cancer (BC) is the most frequent cancer and the leading cause of cancer-related death in women. The French National Cancer Institute has created a national cancer cohort to promote cancer research and improve our understanding of cancer using the National Health Data System (SNDS). This cohort amalgamates all cancer sites, with no detailed separate data for early BC. Objectives: We describe the French Early Breast Cancer Cohort (FRESH). Methods: All French women aged 18 years or over, with early-stage BC newly diagnosed between January 1, 2011 and December 31, 2017, treated by surgery and registered in the general health insurance coverage plan were included in the cohort. Patients with suspected locoregional or distant metastases at diagnosis were excluded. BC treatments (surgery, chemotherapy, targeted therapy, radiotherapy, endocrine therapy), and diagnostic procedures (biopsy, cytology, imaging) were extracted from hospital discharge reports, outpatient care notes or pharmacy drug delivery data. BC subtype was inferred from the treatments received. Results: We included 235,368 patients with early BC in the cohort (median age: 60 years). BC subtype distribution was as follows: luminal (80.2%), triple-negative (TNBC, 9.5%); HER2 + (10.3%), or unidentifiable ( n =44,388, 18.9% of the cohort). Most patients underwent radiotherapy ( n =200,685, 85.3%) and endocrine therapy ( n =165,655, 70.4%), and 38.3% ( n =90,252) received chemotherapy. Treatments and care pathways are described. Conclusion: The FRESH Cohort is an unprecedented population-based resource facilitating future large-scale real-life studies aiming to improve care pathways and quality of care for BC patients.